English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

nfliximab (formerly cA2, Centocor, Inc, USA) is a biological agent that was first reported for the treatment of Crohn’s disease in 1995 (1). It is a chimeric mouse-human immunoglobulin G1 monoclonal antibody to tumour necrosis factor alpha (TNF-α), which is thought to play an important role as a mediator of inflammation in Crohn’s disease. Although it neutralizes TNF, antibody infusions also cause other immunological effects that are less well defined, including changes in cell lysis through complement fixation or antibody-dependent cell-mediated cytotoxicity (2,3). Indeed, in Crohn’s disease tissues, intestinal mucosal cells have been shown to express more TNF (as well as other inflammatory mediators) than healthy individuals (4-6). TNF may regulate some components of the immune response, including those associated with intestinal inflam

Infliximab for Crohn's Disease: More Questions than Answers